Clinical activity of regorafenib in elderly patients with recurrent glioblastoma

• DOI: 10.3892/mco.2023.2605
• Publication Date: 2023-01-10T11:17:00Z
• Authors: Morena Fasano; Mario Pirozzi; Vincenzo Famiglietti; Sergio Facchini; Marianna Caterino; Mara Caroprese; Angela Barillaro; Ilaria Di Giovanni; Annunziata Auriemma; Silvia Ileana Sar...; Teresa Somma; Domenico Solari; Marco Bocchetti; Manuel Conson; Roberto Pacelli; Fortunato Ciardiello; Raffaele Addeo
• Keywords: Regorafenib; Clinical endpoint; Isocitrate dehydrogenase

Glioblastoma multiforme is one of the most frequent and aggressive primary tumors in central nervous system, representing >60% all brain adults. Despite treatment, prognosis remains poor with if not patients experiencing disease recurrence a 2-year survival rate 27%. At present, no confirmed standard treatment exists for recurrent glioblastoma. Regorafenib few options available, based on results from REGOMA trial. In present study, real-life retrospective investigation role regorafenib glioblastoma (>60 years old) two main Oncological Units South Italy (Azienda Ospedaliera Universitaria Luigi Vanvitelli, Naples, Ospedale Civile San Giovanni di Dio, Frattamaggiore, Italy), was performed. The endpoint overall (OS), whereas progression-free (PFS), objective response control were secondary endpoints. Survival then analyzed according to age, isocitrate dehydrogenase (IDH) methylated methylguanine-DNA-methyltransferase (MGMT) status. A total 56 met eligibility criteria. intention treat population median PFS (mPFS) 4.1 months OS (mOS) 6.8 months. Age did appear have significant influence mPFS. mOS MGMT-methylated improved compared that unmethylated group (7.7 vs. 5.6 months). Both mPFS longer IDH-mutant patients. study first real life analyses line be prognostic factor, thus suggesting choice should different elderly. MGMT methylation appeared OS. To best our knowledge, this report activity older and, while statistically significant, these further studies.